Novelion Therapeutics Inc. Common Shares
NVLN
NVLN was delisted on the 8th of October, 2019.
31 hedge funds and large institutions have $6.91M invested in Novelion Therapeutics Inc. Common Shares in 2019 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 5 closing their positions.
48% more call options, than puts
Call options by funds: $108K | Put options by funds: $73K
29% more capital invested
Capital invested by funds: $5.35M → $6.91M (+$1.56M)
11% less funds holding
Funds holding: 35 → 31 (-4)
29% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 7
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$2.33M |
| 2 |
EIG
EdgePoint Investment Group
Toronto,
Ontario, Canada
|
+$195K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$20.1K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$1.56K |
| 5 |
Morgan Stanley
New York
|
+$1.28K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HVC
Healthcare Value Capital
Woodcliff Lake,
New Jersey
|
-$290K |
| 2 |
HCM
Highbridge Capital Management
New York
|
-$244K |
| 3 |
Goldman Sachs
New York
|
-$37.6K |
| 4 |
Millennium Management
New York
|
-$13K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$10K |
NVLN Hedge Fund Activity: Q3 2019 in Review
31 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Novelion Therapeutics Inc. Common Shares (NVLN) for Q3 2019, worth a combined $6.91M — up 29% from $5.35M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of NVLN and 1 opened new positions — a net loss of 4 holders — while 7 trimmed existing stakes and 5 added.
The largest buyer was Stonepine Capital Management, adding an estimated $2.33M. The largest seller was Healthcare Value Capital, cutting an estimated $290K.
- 31 institutional investors held Novelion Therapeutics Inc. Common Shares (NVLN) as of Q3 2019, down from 35 in Q2 2019.
- Funds reported $6.91M of Novelion Therapeutics Inc. Common Shares stock for Q3 2019, up 29% quarter-over-quarter.
- 1 fund opened new Novelion Therapeutics Inc. Common Shares positions in Q3 2019 and 5 closed out, a net change of -4 holders.
- The largest Novelion Therapeutics Inc. Common Shares buyer in Q3 2019 was Stonepine Capital Management, an estimated $2.33M added.
- The largest Novelion Therapeutics Inc. Common Shares seller in Q3 2019 was Healthcare Value Capital, an estimated $290K sold.
Based on aggregated 13F filings for Q3 2019.